Experimental pill targets tough melanoma after immunotherapy fails

NCT ID NCT07237100

Recruiting now Disease control Sponsor: Kevin Kim, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study is testing an oral drug called mirdametinib in 10 people with advanced melanoma that has a specific gene change (NF1 mutation) and has stopped responding to standard immunotherapy. The main goal is to see if the drug can shrink tumors and if it is safe enough to study further. This is an early-stage trial, so results are not yet proven.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirdametinib (a kinase inhibitor taken by mouth)
What this could lead to: If it works, this could point toward a new treatment option for people with a specific genetic type of advanced melanoma that has stopped responding to immunotherapy.
What could go wrong: This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma neurofibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED UNRESECTABLE MELANOMA METASTATIC MELANOMA

Contacts and locations

Locations

California Pacific Medical Center - Sutter Health
RECRUITING

San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.